Vol. 20/No. 1 | OncologyLive

CDK4/6 Inhibitors Explored in Adjuvant Breast Cancer Setting

January 10, 2019

Recently, CDK 4/6 inhibitors have been changing practice in advanced HR-positive breast cancer, with 3 agents now having FDA-approved indications for use with endocrine therapy in the first-line setting.

Study Finds No Cognitive Effects From Endocrine Therapy

January 08, 2019

Endocrine therapy, commonly used for lengthy periods in the adjuvant treatment of patients with breast cancer, does not have a detrimental effect on cognitive function in survivors of early-stage disease.

AI Will Converge With Physician-Directed Care

January 05, 2019

Improvements and greater familiarity with artificial intelligence will lead to systems of checks and balances that will create trust and fulfill the promise of computer-assisted precision medicine.

Drugs Make Progress in Breaching the Blood-Brain Barrier

January 04, 2019

Novel agents are showing impressive ability to cross the blood–brain barrier and impair tumor development in several malignancies, raising the prospect of achieving a long-elusive goal of anticancer therapy.

Looking for Zebras in Metastatic Colorectal Cancer

January 04, 2019

During a recent OncLive Peer Exchange®, a panel of CRC experts discussed the heterogeneity of metastatic CRC and the need to identify patient subsets within this disease to enable a precision medicine approach.